Abstract
Reshma Mahtani, DO, and Lisa Hineman, MS, AOCN®, PHN, ANP-C, reviewed landmark clinical trials of adjuvant therapies for women with HER2–positive breast cancer and emphasized the key role of advanced practitioners in managing adverse events, notably diarrhea.
